Movement Disorders (revue)

Attention, ce site est en cours de développement !
Attention, site généré par des moyens informatiques à partir de corpus bruts.
Les informations ne sont donc pas validées.

Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.

Identifieur interne : 001457 ( Ncbi/Curation ); précédent : 001456; suivant : 001458

Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.

Auteurs : D. Bravi [États-Unis] ; J J Anderson ; F. Dagani ; T L Davis ; R. Ferrari ; M. Gillespie ; T N Chase

Source :

RBID : pubmed:1620140

English descriptors

Abstract

Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.

DOI: 10.1002/mds.870070307
PubMed: 1620140

Links toward previous steps (curation, corpus...)


Links to Exploration step

pubmed:1620140

Le document en format XML

<record>
<TEI>
<teiHeader>
<fileDesc>
<titleStmt>
<title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title>
<author>
<name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name>
<affiliation wicri:level="2">
<nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name>
</author>
<author>
<name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name>
</author>
<author>
<name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name>
</author>
<author>
<name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name>
</author>
<author>
<name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name>
</author>
<author>
<name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name>
</author>
</titleStmt>
<publicationStmt>
<idno type="wicri:source">PubMed</idno>
<date when="1992">1992</date>
<idno type="RBID">pubmed:1620140</idno>
<idno type="pmid">1620140</idno>
<idno type="doi">10.1002/mds.870070307</idno>
<idno type="wicri:Area/PubMed/Corpus">004D33</idno>
<idno type="wicri:Area/PubMed/Curation">004D33</idno>
<idno type="wicri:Area/PubMed/Checkpoint">004D57</idno>
<idno type="wicri:Area/Ncbi/Merge">001457</idno>
<idno type="wicri:Area/Ncbi/Curation">001457</idno>
</publicationStmt>
<sourceDesc>
<biblStruct>
<analytic>
<title xml:lang="en">Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.</title>
<author>
<name sortKey="Bravi, D" sort="Bravi, D" uniqKey="Bravi D" first="D" last="Bravi">D. Bravi</name>
<affiliation wicri:level="2">
<nlm:affiliation>Experimental Therapeutics Branch, NINDS, NIH, Bethesda, Maryland 20892.</nlm:affiliation>
<country xml:lang="fr">États-Unis</country>
<placeName>
<region type="state">Maryland</region>
</placeName>
<wicri:cityArea>Experimental Therapeutics Branch, NINDS, NIH, Bethesda</wicri:cityArea>
</affiliation>
</author>
<author>
<name sortKey="Anderson, J J" sort="Anderson, J J" uniqKey="Anderson J" first="J J" last="Anderson">J J Anderson</name>
</author>
<author>
<name sortKey="Dagani, F" sort="Dagani, F" uniqKey="Dagani F" first="F" last="Dagani">F. Dagani</name>
</author>
<author>
<name sortKey="Davis, T L" sort="Davis, T L" uniqKey="Davis T" first="T L" last="Davis">T L Davis</name>
</author>
<author>
<name sortKey="Ferrari, R" sort="Ferrari, R" uniqKey="Ferrari R" first="R" last="Ferrari">R. Ferrari</name>
</author>
<author>
<name sortKey="Gillespie, M" sort="Gillespie, M" uniqKey="Gillespie M" first="M" last="Gillespie">M. Gillespie</name>
</author>
<author>
<name sortKey="Chase, T N" sort="Chase, T N" uniqKey="Chase T" first="T N" last="Chase">T N Chase</name>
</author>
</analytic>
<series>
<title level="j">Movement disorders : official journal of the Movement Disorder Society</title>
<idno type="ISSN">0885-3185</idno>
<imprint>
<date when="1992" type="published">1992</date>
</imprint>
</series>
</biblStruct>
</sourceDesc>
</fileDesc>
<profileDesc>
<textClass>
<keywords scheme="KwdEn" xml:lang="en">
<term>Age Factors</term>
<term>Blood Glucose (metabolism)</term>
<term>Blood Platelets (drug effects)</term>
<term>Blood Platelets (physiology)</term>
<term>Carbidopa (administration & dosage)</term>
<term>Drug Therapy, Combination</term>
<term>Energy Metabolism (drug effects)</term>
<term>Energy Metabolism (physiology)</term>
<term>Female</term>
<term>Humans</term>
<term>Lactates (blood)</term>
<term>Lactic Acid</term>
<term>Levodopa (administration & dosage)</term>
<term>Lisuride (administration & dosage)</term>
<term>Male</term>
<term>Middle Aged</term>
<term>Mitochondria (drug effects)</term>
<term>Mitochondria (physiology)</term>
<term>Oxygen Consumption (drug effects)</term>
<term>Oxygen Consumption (physiology)</term>
<term>Parkinson Disease (drug therapy)</term>
<term>Parkinson Disease (physiopathology)</term>
<term>Receptors, Dopamine (drug effects)</term>
<term>Receptors, Dopamine (physiology)</term>
<term>Selegiline (administration & dosage)</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="administration & dosage" xml:lang="en">
<term>Carbidopa</term>
<term>Levodopa</term>
<term>Lisuride</term>
<term>Selegiline</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="blood" xml:lang="en">
<term>Lactates</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="drug effects" xml:lang="en">
<term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" type="chemical" qualifier="metabolism" xml:lang="en">
<term>Blood Glucose</term>
</keywords>
<keywords scheme="MESH" qualifier="drug effects" xml:lang="en">
<term>Blood Platelets</term>
<term>Energy Metabolism</term>
<term>Mitochondria</term>
<term>Oxygen Consumption</term>
</keywords>
<keywords scheme="MESH" qualifier="drug therapy" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" qualifier="physiology" xml:lang="en">
<term>Blood Platelets</term>
<term>Energy Metabolism</term>
<term>Mitochondria</term>
<term>Oxygen Consumption</term>
<term>Receptors, Dopamine</term>
</keywords>
<keywords scheme="MESH" qualifier="physiopathology" xml:lang="en">
<term>Parkinson Disease</term>
</keywords>
<keywords scheme="MESH" xml:lang="en">
<term>Age Factors</term>
<term>Drug Therapy, Combination</term>
<term>Female</term>
<term>Humans</term>
<term>Lactic Acid</term>
<term>Male</term>
<term>Middle Aged</term>
</keywords>
</textClass>
</profileDesc>
</teiHeader>
<front>
<div type="abstract" xml:lang="en">Oxygen consumption and enzyme activity were evaluated in platelet mitochondria from 17 patients with Parkinson's disease. In comparison with age-matched controls, no consistent abnormality could be discerned in complex I, complex II-III, or complex IV oxygen consumption, or in the enzyme activity of these respiratory chain complexes. Neither chronic therapy with levodopa/carbidopa alone nor in combination with deprenyl significantly affected any measure of mitochondrial respiratory function. There was no discernible relationship between patient age or disease severity and any parameter of mitochondrial respiration. Moreover, blood lactate levels following glucose loading were not different in patients and controls. These results fail to support the occurrence of a generalized defect in any mitochondrial respiratory function in Parkinson's disease.</div>
</front>
</TEI>
</record>

Pour manipuler ce document sous Unix (Dilib)

EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Ncbi/Curation
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001457 | SxmlIndent | more

Ou

HfdSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd -nk 001457 | SxmlIndent | more

Pour mettre un lien sur cette page dans le réseau Wicri

{{Explor lien
   |wiki=    Wicri/Santé
   |area=    MovDisordV3
   |flux=    Ncbi
   |étape=   Curation
   |type=    RBID
   |clé=     pubmed:1620140
   |texte=   Effect of aging and dopaminomimetic therapy on mitochondrial respiratory function in Parkinson's disease.
}}

Pour générer des pages wiki

HfdIndexSelect -h $EXPLOR_AREA/Data/Ncbi/Curation/RBID.i   -Sk "pubmed:1620140" \
       | HfdSelect -Kh $EXPLOR_AREA/Data/Ncbi/Curation/biblio.hfd   \
       | NlmPubMed2Wicri -a MovDisordV3 

Wicri

This area was generated with Dilib version V0.6.23.
Data generation: Sun Jul 3 12:29:32 2016. Site generation: Wed Feb 14 10:52:30 2024